ENO1 and pancreatic neoplasm: These vaccines have been studied in relation to a range of targets of pancreatic cancer, such as MUC1 [113], surviving [114,115], enolase 1 (ENO1) [116], VEGFR-2 [117], and fibroblast activation protein α-expressing cancer-associated fibroblasts (FAPα+ CAFs) [115].